Tags

Type your tag names separated by a space and hit enter

Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan.
Br J Cancer. 1999 Aug; 80(11):1838-43.BJ

Abstract

The incidence of breast cancer has been greatly increasing in Taiwan over the past two decades. Since cytochrome P4501A1 (CYP1A1) is involved in the metabolism of environmental carcinogens or oestrogen, we hypothesized that CYP1A1 genetic polymorphism may be a susceptibility factor for breast cancer. This hypothesis was evaluated in this case control study of 150 breast cancer patients and 150 healthy controls among Chinese women. Two CYP1A1 polymorphisms were studied, one containing a new Msp1 site and the other located in axon 7 and resulting in the replacement of an isoleucine (Ile) residue by a valine (Val). After simultaneously considering the known or significant risk factors for breast cancer, including the age of study participants, positive family history of breast cancer, early menarche (< or = 13 years), nulliparity and late first full-term pregnancy (> or = 30 years), hormone replacement therapy and smoking, the CYP1A1 Msp1 polymorphism was found to be a significant factor in determining the risk of breast cancer. The homozygous variant was the most susceptible genotype with an adjusted odds ratio of 1.98 (95% confidence interval (CI) = 1.01-3.99) compared with the non-homozygous variants (the homozygous wild-type and the heterozygous variant). In contrast, the CYP1A1 Ile/Val polymorphism was not significantly associated with breast cancer development (adjusted OR = 1.07, 95% CI = 0.64-1.78). Interestingly, the Msp1 polymorphism was especially significant in postmenopausal women, but not in premenopausal women. Further stratification analysis in postmenopausal women who were non-smokers and with no history of hormone replacement therapy showed the cancer risk due to the Msp1 variant to be more significant in women with early menarche. We conclude that CYP1A1 polymorphism is a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Further study with a large sample size should be considered to address issues of interactions between CYP1A1 and other risk factors.

Authors+Show Affiliations

Department of Surgery, College of Medicine, National Taiwan University, Taipei.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10468307

Citation

Huang, C S., et al. "Cytochrome P4501A1 Polymorphism as a Susceptibility Factor for Breast Cancer in Postmenopausal Chinese Women in Taiwan." British Journal of Cancer, vol. 80, no. 11, 1999, pp. 1838-43.
Huang CS, Shen CY, Chang KJ, et al. Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer. 1999;80(11):1838-43.
Huang, C. S., Shen, C. Y., Chang, K. J., Hsu, S. M., & Chern, H. D. (1999). Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. British Journal of Cancer, 80(11), 1838-43.
Huang CS, et al. Cytochrome P4501A1 Polymorphism as a Susceptibility Factor for Breast Cancer in Postmenopausal Chinese Women in Taiwan. Br J Cancer. 1999;80(11):1838-43. PubMed PMID: 10468307.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. AU - Huang,C S, AU - Shen,C Y, AU - Chang,K J, AU - Hsu,S M, AU - Chern,H D, PY - 1999/9/1/pubmed PY - 1999/9/1/medline PY - 1999/9/1/entrez SP - 1838 EP - 43 JF - British journal of cancer JO - Br. J. Cancer VL - 80 IS - 11 N2 - The incidence of breast cancer has been greatly increasing in Taiwan over the past two decades. Since cytochrome P4501A1 (CYP1A1) is involved in the metabolism of environmental carcinogens or oestrogen, we hypothesized that CYP1A1 genetic polymorphism may be a susceptibility factor for breast cancer. This hypothesis was evaluated in this case control study of 150 breast cancer patients and 150 healthy controls among Chinese women. Two CYP1A1 polymorphisms were studied, one containing a new Msp1 site and the other located in axon 7 and resulting in the replacement of an isoleucine (Ile) residue by a valine (Val). After simultaneously considering the known or significant risk factors for breast cancer, including the age of study participants, positive family history of breast cancer, early menarche (< or = 13 years), nulliparity and late first full-term pregnancy (> or = 30 years), hormone replacement therapy and smoking, the CYP1A1 Msp1 polymorphism was found to be a significant factor in determining the risk of breast cancer. The homozygous variant was the most susceptible genotype with an adjusted odds ratio of 1.98 (95% confidence interval (CI) = 1.01-3.99) compared with the non-homozygous variants (the homozygous wild-type and the heterozygous variant). In contrast, the CYP1A1 Ile/Val polymorphism was not significantly associated with breast cancer development (adjusted OR = 1.07, 95% CI = 0.64-1.78). Interestingly, the Msp1 polymorphism was especially significant in postmenopausal women, but not in premenopausal women. Further stratification analysis in postmenopausal women who were non-smokers and with no history of hormone replacement therapy showed the cancer risk due to the Msp1 variant to be more significant in women with early menarche. We conclude that CYP1A1 polymorphism is a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Further study with a large sample size should be considered to address issues of interactions between CYP1A1 and other risk factors. SN - 0007-0920 UR - https://www.unboundmedicine.com/medline/citation/10468307/Cytochrome_P4501A1_polymorphism_as_a_susceptibility_factor_for_breast_cancer_in_postmenopausal_Chinese_women_in_Taiwan_ L2 - http://dx.doi.org/10.1038/sj.bjc.6690608 DB - PRIME DP - Unbound Medicine ER -